EQS-News: APONTIS PHARMA: Changes in the management board

APONTIS PHARMA: Changes in the management board

Monheim am Rhein, 20 August 2025. Bruno Wohlschlegel, CEO of APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company for single-pill combinations in Germany, is to leave the company at the end of August 2025 with the end of his contract. Wohlschlegel will take on an advisory role with the company to support the transition to new leadership through to end of September. A successor will be announced in due course.

Wohlschlegel was appointed CEO of APONTIS PHARMA in September 2023 to implement the restructuring of the company and achieve a return to profitability based on a long-term growth strategy. Following the implementation of a successful performance and efficiency improvement program with cost reductions, a realignment of sales, and a new go-to-market approach, the company was able to make significant progress in spring 2024 and return to growth and profitability in fiscal year 2024.

In fall 2024, the pharmaceutical company Zentiva announced a voluntary public purchase offer for the shares of APONTIS PHARMA. At the company's Annual General Meeting on July 29, 2025, the shareholders approved the merger squeeze-out, i.e. the transfer of the minority shareholders’ shares to Zentiva against payment of a cash compensation in the amount of EUR 10.40 per share. Upon registration of the merger squeeze-out with the commercial register, APONTIS PHARMA will cease to exist. The current inclusion of the APONTIS PHARMA shares in trading on the open market is expected to end shortly after the merger squeeze-out has taken effect.

„With the decision of the Annual General Meeting on the merger squeeze-out, APONTIS PHARMA will be fully integrated into Zentiva Group. My task of restructuring the company, restoring profitability, and developing a long-term strategy has thus been successfully completed ahead of schedule. After just a few months, we were already able to show the first positive results of our restructuring program. The co-marketing agreement with Novartis, the successful development of single-pill combinations and, explicitly, the purchase offer by Zentiva are proof of this. The entire team, including the Executive Board and employees of APONTIS PHARMA, has done a tremendous job. I am delighted to be handing over a well-positioned company with a motivated team to the new owners“, says Bruno Wohlschlegel, CEO of APONTIS PHARMA.

„Bruno Wohlschlegel has made an outstanding contribution to the restructuring and realignment of APONTIS PHARMA over the past two years. After the company faced considerable challenges in the summer of 2023, he and his team developed and successfully implemented a far-reaching performance and efficiency improvement program. He returned the company to profitability faster than expected and increased the market presence of single-pill combinations. The Supervisory Board valued his input, expertise, and experience. We wish him all the best for his future plans and are delighted that he will continue to support the company with his experience during the transition period“, says Matthias Wiedenfels, Chairman of the Supervisory Board of APONTIS PHARMA.

About APONTIS PHARMA

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, marketing and distributing a broad portfolio of single-pill combinations and other medicines since 2013, with a particular focus on cardiovascular diseases such as hypertension, hyperlipidaemia and secondary prevention, as well as asthma. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Presse Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330